Infliximab, a TNF-α inhibitor, was shown to lower 28-day mortality in a selected group of patients with COVID-19, suggesting a role of TNF-α in the pathogenesis of more severe COVID-19 [39]. The gene discussed is TNF; the disease is COVID-19.